Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, Follicular 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Non-Hodgkin 10Lymphoma 10Lymphoma, Mantle-Cell 7Recurrence 5Lymphoma, B-Cell, Marginal Zone 5Neoplasms 4Lymphoma, B-Cell 4Leukemia, B-Cell 3Neoplasm, Residual 2Burkitt Lymphoma 2Mature B-Cell Malignancies 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Leukemia 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

Rituximab 13Cyclophosphamide 9Magnetic Resonance Spectroscopy 7Lenalidomide 7venetoclax 6obinutuzumab 5ibrutinib 5Specimen Handling 5fludarabine phosphate 4fludarabine 4Whole-Body Irradiation 4Prednisone 4CT-P10 4Biopsy 4zanubrutinib 3orelabrutinib 3Vincristine 3Mycophenolic Acid 3Cyclosporine 3polatuzumab vedotin 2pirtobrutinib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Doxorubicin 2Busulfan 2Bendamustine Hydrochloride 2voruciclib 1treosulfan 1tafasitamab 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × obinutuzumab × 90 days × Clear all
NCT05100862 2026-05-27

MAHOGANY

BeOne Medicines

Phase 3 Recruiting
780 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05169658 2026-05-13

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Completed
42 enrolled 10 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT03322865 2026-05-06

Obinutuzumab in Marginal Zone Lymphoma

University of Ulm

Phase 2 Active not recruiting
56 enrolled
Lymphoid

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT06793189 2026-03-24

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Ruijin Hospital

Phase 2 Recruiting
145 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT05783596 2026-03-16

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡